ArticleJournal of microbiology and biotechnology2025
Evaluating the Antifungal Potential of Autophagy-Related Protein 4 (ATG4) Inhibitors against Human Fungal Pathogens.
Article in Journal of microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular frontiers of fungal autophagy: from molecular mechanisms to potential targets for antifungal drug discovery.World journal of microbiology & biotechnology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Emerging fungal pathogens pose a significant threat to global public health. Despite the availability of antifungal agents, their clinical efficacy is increasingly challenged by the rise of fungicide-resistant strains. Therefore, identifying novel therapeutic targets and ensuring the safe application of antifungal agents are critical for advancing treatment strategies. Autophagy, a fundamental cellular process that maintains intracellular homeostasis by degrading and recycling dysfunctional proteins and organelles, is implicated in fungal pathogenicity. It indicates that inhibition of autophagy represents a promising approach for antifungal development. In this study, we evaluate the antifungal potential of autophagy inhibitors targeting the Autophagy-related protein 4 (ATG4)-mediated cleavage of Autophagy-related protein 8 (ATG8). Our findings demonstrate that ebselen and its analogs effectively inhibit ATG4 activity in
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.